MAPT and Alzheimer disease: This system proposes classifying AD in-vivo through a variety of imaging techniques (i.e. PET, MRI) and fluid biomarkers (i.e. CSF protein biomarkers of AD) that measure Aβ (A), tau (T), and degree of neurodegeneration (N) (166).